TY - JOUR
T1 - Advances in the management of cutaneous toxicities of targeted therapies
AU - Robert, Caroline
AU - Sibaud, Vincent
AU - Mateus, Christine
AU - Cherpelis, Basil S.
PY - 2012/4/1
Y1 - 2012/4/1
N2 - Contrary to what might have been expected, the effects of targeted therapies are not limited to the cancer cells and are unfortunately associated with many and numerous adverse events. Dermatologic manifestations are among the most frequently observed, and, when severe and/or protracted, they inevitably impact the quality of life of patients. Management of these various side effects is empirical and mostly based on expert advice and consensus. We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors.
AB - Contrary to what might have been expected, the effects of targeted therapies are not limited to the cancer cells and are unfortunately associated with many and numerous adverse events. Dermatologic manifestations are among the most frequently observed, and, when severe and/or protracted, they inevitably impact the quality of life of patients. Management of these various side effects is empirical and mostly based on expert advice and consensus. We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=84859387313&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2012.01.009
DO - 10.1053/j.seminoncol.2012.01.009
M3 - Article
C2 - 22484194
AN - SCOPUS:84859387313
SN - 0093-7754
VL - 39
SP - 227
EP - 240
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 2
ER -